NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.

The term "omics" refers to the study of the entirety of molecular mechanisms that happen inside an organism. With the advent ...

SCIEX, a global leader in life science analytical technologies, has enhanced its high-resolution accurate mass spectrometry ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

The Medicare coverage story of the Cardiomems device has a Homeric air about it, spanning nearly a decade starting with an adverse local coverage determination in 2016. Abbott Park, Ill.-based Abbott ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Made in collaboration with Korean start-up Nanoentek, this tabletop device uses advanced proteomics (the study of how protein ...

Rheumatoid arthritis is a crippling condition affecting 1.3 million people. To date, the standard of care has been to head ...

OncoHost, a global leader in next-generation precision oncology dedicated to advancing personalized cancer therapy, announced today that it has been named a winner in the 2025 BIG Innovation Awards.